Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Superkiller complex protein 3 (SKI3) is a core structural subunit of the cytoplasmic SKI complex, which partners with the RNA exosome to facilitate the 3'-to-5' degradation of cytoplasmic mRNAs as part of mRNA surveillance and decay pathways[1][2][3][4][5]. SKI3 is a large tetratricopeptide repeat (TPR) protein, acting as a scaffold within the SKI complex that assembles with the RNA helicase SKI2 and the WD repeat protein SKI8 in a conserved 1:1:2 stoichiometry[1][2][3][5]. While SKI2 provides RNA helicase activity, SKI3 and SKI8 are considered non-enzymatic structural components that coordinate complex assembly and modulation[1][2][3]. The SKI complex is conserved from yeast (where it was historically associated with viral resistance) to humans, where the SKI3 homolog is encoded by the TTC37 gene[1][2][3]. In humans, biallelic mutations in TTC37/SKI3 cause tricho-hepatic-enteric syndrome, a rare multisystem disorder. In general, SKI3 is not considered a direct therapeutic target (such as a receptor, enzyme, or transporter), nor are there currently drugs known to act on SKI3 or the SKI complex in clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Superkiller complex protein 3 (SKI3).